Chairman of the Board
Over the course of his career, Roger Pomerantz led the development of 12 infectious disease drugs that have been approved and launched worldwide and established an outstanding track record in licensing and acquisitions. Following an academic career, most recently as an endowed, tenured Professor of Medicine, Biochemistry and Molecular Pharmacology, and Chief of Infectious Diseases at Thomas Jefferson University and Medical School, he joined Johnson & Johnson’s Tibotec Pharmaceuticals unit as President.
Dr. Pomerantz subsequently moved to Merck Research Labs, where he served as global head of the infectious diseases franchise and senior vice president and then as worldwide head of licensing and acquisitions, senior vice president at Merck & Co. Following Merck, Dr. Pomerantz served as the president, chief executive officer and chairman of the board at Seres Therapeutics, where he continues to serve as chairman. Dr. Pomerantz joined Contrafect in 2014 to serve as the vice chairman of the board of directors and now currently serves as president, chief executive officer and chairman of the company. Dr. Pomerantz also serves on several other boards, including Intec Pharma, Inc. Dr. Pomerantz earned a bachelor of arts degree in biochemistry from Johns Hopkins University and a medical doctor degree at the Johns Hopkins University School of Medicine in Baltimore. Dr. Pomeranz did his post-graduate medical training at the Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) in Boston, where he did a subspecialty fellowship in infectious diseases. Dr. Pomerantz was also the chief resident at MGH. He did post-doctoral training in molecular retrovirology in the laboratory of Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology in Cambridge, Mass.
Dr. Pomerantz is board certified in both internal medicine and infectious diseases.